Neuracle Science
PrivateLast Round
Private Placement
May 13, 2024
Est. Valuation
$54.56M
Total Funding Raised
$47.82M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Neuracle Science operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Private Placement round in May 2024.
Neuracle Science is a biopharmaceutical company that develops antibody therapeutics for the treatment of neurodegenerative and sensory nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neuracle Science Comparables
Compare Neuracle Science with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alector | 74% | |
| Acousia Therapeutics GmbH | 72% | |
| Strekin AG | 68% |
For institutional investors. Book with your work email.
Neuracle Science Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | May 13, 2024 | ||||
| Series C | Jun 13, 2019 | ||||
| Series B | Aug 14, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neuracle Science Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Seven Tree Equity Partners | Series C |
| Shinhan Securities | Series C |
| BNK Asset Management | Series C |
| Arche Investment | Series B, Private Placement, Series C |
| Industrial Bank of Korea | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 56% MoM.
- Aug 1, 2026
Grew 16% QoQ from 19 to 22 employees.
For institutional investors. Book with your work email.
Neuracle Science Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neuracle Science's valuation, stock price, and market status.
Is Neuracle Science a public or private company?
Neuracle Science is a private company.
What is the current stock price of Neuracle Science?
Neuracle Science is a private company, so its shares have no public market price. Caplight tracks Neuracle Science's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neuracle Science worth (valuation)?
Neuracle Science's valuation is estimated at $54.6M based on funding round data.
Can I buy Neuracle Science stock?
Neuracle Science shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neuracle Science's last funding round?
Neuracle Science's most recent funding round was Private Placement on May 13, 2024.
Who are the main investors in Neuracle Science?
Key investors in Neuracle Science include Seven Tree Equity Partners, Shinhan Securities, BNK Asset Management, Arche Investment, Industrial Bank of Korea.
Will Neuracle Science IPO soon?
No public IPO plans have been announced for Neuracle Science.
How can I track Neuracle Science secondary market activity?
Caplight tracks bids, offers, and trades in Neuracle Science's shares on secondary markets.